Journal of Thoracic Oncology最新文献

筛选
英文 中文
Erratum to 'Unveiling the Landscape of Uncommon EGFR Mutations in NSCLC-A Systematic Review' [Journal of Thoracic Oncology Volume 19 Issue 7 (2024) 973-983]. “揭示非小细胞肺癌中罕见EGFR突变的景观-系统评价”的勘误[Journal of Thoracic Oncology vol . 19 Issue 7(2024) 973-983]。
IF 21 1区 医学
Journal of Thoracic Oncology Pub Date : 2025-07-11 DOI: 10.1016/j.jtho.2025.06.026
Maxime Borgeaud, Kaushal Parikh, Giuseppe Luigi Banna, Floryane Kim, Timothée Olivier, Xiuning Le, Alfredo Addeo
{"title":"Erratum to 'Unveiling the Landscape of Uncommon EGFR Mutations in NSCLC-A Systematic Review' [Journal of Thoracic Oncology Volume 19 Issue 7 (2024) 973-983].","authors":"Maxime Borgeaud, Kaushal Parikh, Giuseppe Luigi Banna, Floryane Kim, Timothée Olivier, Xiuning Le, Alfredo Addeo","doi":"10.1016/j.jtho.2025.06.026","DOIUrl":"https://doi.org/10.1016/j.jtho.2025.06.026","url":null,"abstract":"","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":" ","pages":""},"PeriodicalIF":21.0,"publicationDate":"2025-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144608699","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Molecular Tumor Boards: A consensus statement from the International Association for the Study of Lung Cancer. 分子肿瘤委员会:国际肺癌研究协会的共识声明。
IF 21 1区 医学
Journal of Thoracic Oncology Pub Date : 2025-07-07 DOI: 10.1016/j.jtho.2025.07.009
Mihaela Aldea, Julia K Rotow, Maria Arcila, Matthew Hatton, Lynette Sholl, Christian Rolfo, Marco Tagliamento, Teodora Radonic, Kurt A Schalper, Vivek Subbiah, Umberto Malapelle, Anja C Roden, Rami Manochakian, Ming-Sound Tsao, Helena Linardou, Rina Hui, Silvia Novello, Alastair Greystoke, Anjali Saqi, Sylvie Lantuejoul, David M Hwang, Kelly Nevins, Murry Wynes, Saiama Waqar, Yuchen Han, Yasushi Yatabe, Wei-Chin Chang, Takuo Hayashi, Tae-Jung Kim, Paul Hofman, Fabio Tavora, Fred R Hirsch, Valeria Denninghoff, Natasha B Leighl, Alexander Drilon, Wendy A Cooper, Sanja Dacic, Pranshu Mohindra, Nick Pavlakis, Fernando Lopez-Rios
{"title":"Molecular Tumor Boards: A consensus statement from the International Association for the Study of Lung Cancer.","authors":"Mihaela Aldea, Julia K Rotow, Maria Arcila, Matthew Hatton, Lynette Sholl, Christian Rolfo, Marco Tagliamento, Teodora Radonic, Kurt A Schalper, Vivek Subbiah, Umberto Malapelle, Anja C Roden, Rami Manochakian, Ming-Sound Tsao, Helena Linardou, Rina Hui, Silvia Novello, Alastair Greystoke, Anjali Saqi, Sylvie Lantuejoul, David M Hwang, Kelly Nevins, Murry Wynes, Saiama Waqar, Yuchen Han, Yasushi Yatabe, Wei-Chin Chang, Takuo Hayashi, Tae-Jung Kim, Paul Hofman, Fabio Tavora, Fred R Hirsch, Valeria Denninghoff, Natasha B Leighl, Alexander Drilon, Wendy A Cooper, Sanja Dacic, Pranshu Mohindra, Nick Pavlakis, Fernando Lopez-Rios","doi":"10.1016/j.jtho.2025.07.009","DOIUrl":"https://doi.org/10.1016/j.jtho.2025.07.009","url":null,"abstract":"<p><strong>Context: </strong>Molecular Tumor Boards (MTBs) are multidisciplinary meetings of specialists dedicated to analyzing biomarker test results to provide personalized treatment recommendations. However, global disparities in the successful implementation of MTBs exist, driven by unequal access to molecular diagnostics and supportive multidimensional expertise.</p><p><strong>Objective: </strong>To establish recommendations for MTB implementation, outline practical frameworks for their operation, and address disparities in expertise and resources between new and established MTBs.</p><p><strong>Design: </strong>A modified Delphi method involved 37 international experts in three survey rounds and online meetings, with consensus defined as ≥75% agreement.</p><p><strong>Results: </strong>The panel identified a molecular biologist or pathologist with expertise in molecular diagnostics and tumor-specific medical oncologists as indispensable MTB members. Case selection should reflect institutional expertise and volume, with newer MTBs reviewing less selected cases to gain experience. Regular meetings are advised to avoid delays beyond 14 days from result availability to discussion. Reporting should be standardized to include clinicopathologic data (tumor characteristics, treatment history), biomarker findings (testing results, sample details), and recommendations (treatment, retesting, genetic counseling). Treatment options should be ranked by the level of evidence for actionability and may include options not available locally. Performance evaluation should consider changes in patient management based on MTB input and matched therapy rates.</p><p><strong>Conclusions: </strong>These MTB consensus recommendations are applicable across tumor types, despite being developed by lung cancer and molecular specialists and initiated by the International Association for the Study of Lung Cancer (IASLC). They provide a structured framework for MTB implementation, report standardization, case selection, and quality assessment, aiming to standardize practice and address gaps in expertise for personalized cancer care.</p>","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":" ","pages":""},"PeriodicalIF":21.0,"publicationDate":"2025-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144600867","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
50 years of Progress in Non-Small Cell Lung Cancer: A New Fellow's Guide in the Clinic. 非小细胞肺癌研究50年进展:临床新指南
IF 21 1区 医学
Journal of Thoracic Oncology Pub Date : 2025-07-03 DOI: 10.1016/j.jtho.2025.06.028
Jarushka Naidoo, Abesh Niroula, Dipesh Uprety, Matthew Smeltzer, Nicole Geissen, Raymond U Osarogiagbon, Mari Mino-Kenudson, Yasushi Yatabe, Kristin Higgins, Aakash Desai, Karen L Reckamp, Jessica Jiyeong Lin, Stephen V Liu, Fiona Hegi-Johnson Franzcr, Nagashree Seetharamu, David Harpole, Martin J Edelman
{"title":"50 years of Progress in Non-Small Cell Lung Cancer: A New Fellow's Guide in the Clinic.","authors":"Jarushka Naidoo, Abesh Niroula, Dipesh Uprety, Matthew Smeltzer, Nicole Geissen, Raymond U Osarogiagbon, Mari Mino-Kenudson, Yasushi Yatabe, Kristin Higgins, Aakash Desai, Karen L Reckamp, Jessica Jiyeong Lin, Stephen V Liu, Fiona Hegi-Johnson Franzcr, Nagashree Seetharamu, David Harpole, Martin J Edelman","doi":"10.1016/j.jtho.2025.06.028","DOIUrl":"https://doi.org/10.1016/j.jtho.2025.06.028","url":null,"abstract":"","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":" ","pages":""},"PeriodicalIF":21.0,"publicationDate":"2025-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144567607","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Lazertinib Versus Osimertinib in Previously Untreated EGFR-mutant Advanced NSCLC: A Randomized, Double-blind, Exploratory Analysis From MARIPOSA. 拉泽替尼与奥西替尼在未经治疗的egfr突变晚期NSCLC中的对比:一项来自MARIPOSA的随机、双盲、探索性分析
IF 21 1区 医学
Journal of Thoracic Oncology Pub Date : 2025-07-03 DOI: 10.1016/j.jtho.2025.06.030
Se-Hoon Lee, Shun Lu, Hidetoshi Hayashi, Enriqueta Felip, Alexander I Spira, Nicolas Girard, Yu Jung Kim, Yurii Ostapenko, Pongwut Danchaivijitr, Baogang Liu, Adlinda Alip, Ernesto Korbenfeld, Josiane Mourão Dias, Ki Hyeong Lee, Hailin Xiong, Soon Hin How, Ying Cheng, Gee-Chen Chang, James Chih-Hsin Yang, Benjamin Besse, Michael Thomas, Sujay Shah, Mahadi Baig, Joshua C Curtin, Jiarui Zhang, John Xie, Tao Sun, Seema Sethi, Miao Wang, Elizabeth Fennema, Mahesh Daksh, Mariah Ennis, Joshua M Bauml, Byoung Chul Cho
{"title":"Lazertinib Versus Osimertinib in Previously Untreated EGFR-mutant Advanced NSCLC: A Randomized, Double-blind, Exploratory Analysis From MARIPOSA.","authors":"Se-Hoon Lee, Shun Lu, Hidetoshi Hayashi, Enriqueta Felip, Alexander I Spira, Nicolas Girard, Yu Jung Kim, Yurii Ostapenko, Pongwut Danchaivijitr, Baogang Liu, Adlinda Alip, Ernesto Korbenfeld, Josiane Mourão Dias, Ki Hyeong Lee, Hailin Xiong, Soon Hin How, Ying Cheng, Gee-Chen Chang, James Chih-Hsin Yang, Benjamin Besse, Michael Thomas, Sujay Shah, Mahadi Baig, Joshua C Curtin, Jiarui Zhang, John Xie, Tao Sun, Seema Sethi, Miao Wang, Elizabeth Fennema, Mahesh Daksh, Mariah Ennis, Joshua M Bauml, Byoung Chul Cho","doi":"10.1016/j.jtho.2025.06.030","DOIUrl":"https://doi.org/10.1016/j.jtho.2025.06.030","url":null,"abstract":"<p><strong>Introduction: </strong>Lazertinib is a CNS-penetrant, third-generation epidermal growth factor (EGFR)-tyrosine kinase inhibitor (TKI) that was selected for combination with amivantamab due to its relatively low rates of wild-type EGFR toxicities. In the phase 3 MARIPOSA study, amivantamab plus lazertinib (amivantamab-lazertinib) significantly improved progression-free survival (PFS) and overall survival versus osimertinib in participants with treatment-naïve EGFR-mutant advanced non-small cell lung cancer. A lazertinib monotherapy arm was included to assess the contribution of components in the combination. This is the first randomized, double-blind comparison of 2 third-generation EGFR-TKIs, lazertinib and osimertinib.</p><p><strong>Methods: </strong>In MARIPOSA, 1074 participants were randomized 2:2:1 to receive amivantamab-lazertinib (n=429), osimertinib monotherapy (n=429), or lazertinib monotherapy (n=216). This exploratory analysis compared the efficacy and safety of lazertinib and osimertinib.</p><p><strong>Results: </strong>At a median follow-up of 22.0 months, median PFS was 18.5 months for lazertinib versus 16.6 months for osimertinib (HR, 0.98; 95% CI, 0.79-1.22; P=0.86). PFS results were comparable between arms among predefined subgroups. Among participants with measurable disease at baseline, objective response rate was 83% for lazertinib versus 85% for osimertinib, with a median duration of response among confirmed responders of 16.6 months versus 16.8 months, respectively. Median overall survival was not reached for both arms (HR, 1.00; 95% CI, 0.73-1.38) at the interim analysis. Adverse events for both arms were mostly grade 1-2 and frequently related to EGFR inhibition. Lazertinib was associated with lower rates of QT interval prolongation versus osimertinib.</p><p><strong>Conclusions: </strong>Lazertinib showed comparable efficacy and safety to osimertinib, including in predefined subgroups.</p>","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":" ","pages":""},"PeriodicalIF":21.0,"publicationDate":"2025-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144567608","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Response to the Letter to the Editor: “In Situ Detection of Programmed Cell Death Protein 1 and Programmed Death Ligand 1 Interactions as a Functional Predictor for Response to Immune Checkpoint Inhibition in NSCLC” 对致编辑的信的回复:“原位检测程序性细胞死亡蛋白1和程序性死亡配体1相互作用作为非小细胞肺癌免疫检查点抑制反应的功能预测因子”
IF 21 1区 医学
Journal of Thoracic Oncology Pub Date : 2025-07-01 DOI: 10.1016/j.jtho.2025.04.005
Amanda Lindberg MSc, Patrick Micke MD, PhD, Carina Strell PhD
{"title":"A Response to the Letter to the Editor: “In Situ Detection of Programmed Cell Death Protein 1 and Programmed Death Ligand 1 Interactions as a Functional Predictor for Response to Immune Checkpoint Inhibition in NSCLC”","authors":"Amanda Lindberg MSc,&nbsp;Patrick Micke MD, PhD,&nbsp;Carina Strell PhD","doi":"10.1016/j.jtho.2025.04.005","DOIUrl":"10.1016/j.jtho.2025.04.005","url":null,"abstract":"","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":"20 7","pages":"Pages e87-e89"},"PeriodicalIF":21.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144548362","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Overdiagnosis of Lung Cancer From Low-Dose Computed Tomography Screening in Average-Risk Chinese Populations 中国平均风险人群低剂量ct筛查中肺癌的过度诊断
IF 21 1区 医学
Journal of Thoracic Oncology Pub Date : 2025-07-01 DOI: 10.1016/j.jtho.2025.03.050
Donghui Jin MD, Jiwei Wu MD, Wenqun Xing MD
{"title":"Overdiagnosis of Lung Cancer From Low-Dose Computed Tomography Screening in Average-Risk Chinese Populations","authors":"Donghui Jin MD,&nbsp;Jiwei Wu MD,&nbsp;Wenqun Xing MD","doi":"10.1016/j.jtho.2025.03.050","DOIUrl":"10.1016/j.jtho.2025.03.050","url":null,"abstract":"","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":"20 7","pages":"Pages e89-e90"},"PeriodicalIF":21.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144548363","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Board of Directors 董事会
IF 21 1区 医学
Journal of Thoracic Oncology Pub Date : 2025-07-01 DOI: 10.1016/S1556-0864(25)00729-4
{"title":"Board of Directors","authors":"","doi":"10.1016/S1556-0864(25)00729-4","DOIUrl":"10.1016/S1556-0864(25)00729-4","url":null,"abstract":"","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":"20 7","pages":"Page A3"},"PeriodicalIF":21.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144549165","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Erratum to ‘Diabetic Ketoacidosis During Lorlatinib Treatment: Case Report’ [Journal of Thoracic Oncology Volume 20, Issue 5 (2025) 676-679] 对“Lorlatinib治疗期间糖尿病酮症酸中毒:病例报告”的勘误[Journal of Thoracic Oncology vol . 20, Issue 5(2025) 676-679]。
IF 21 1区 医学
Journal of Thoracic Oncology Pub Date : 2025-07-01 DOI: 10.1016/j.jtho.2025.04.015
Atsushi Yanagisawa MD, Takayuki Shiroyama MD, PhD, Kotaro Miyake MD, PhD, Yoshito Takeda MD, PhD, Atsushi Kumanogoh MD, PhD
{"title":"Erratum to ‘Diabetic Ketoacidosis During Lorlatinib Treatment: Case Report’ [Journal of Thoracic Oncology Volume 20, Issue 5 (2025) 676-679]","authors":"Atsushi Yanagisawa MD,&nbsp;Takayuki Shiroyama MD, PhD,&nbsp;Kotaro Miyake MD, PhD,&nbsp;Yoshito Takeda MD, PhD,&nbsp;Atsushi Kumanogoh MD, PhD","doi":"10.1016/j.jtho.2025.04.015","DOIUrl":"10.1016/j.jtho.2025.04.015","url":null,"abstract":"","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":"20 7","pages":"Page 983"},"PeriodicalIF":21.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144016536","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
In Situ Detection of Programmed Cell Death Protein 1 and Programmed Death Ligand 1 Interactions as a Functional Predictor for Response to Immune Checkpoint Inhibition in NSCLC 原位检测程序性细胞死亡蛋白1和程序性死亡配体1相互作用作为非小细胞肺癌免疫检查点抑制反应的功能预测因子
IF 21 1区 医学
Journal of Thoracic Oncology Pub Date : 2025-07-01 DOI: 10.1016/j.jtho.2025.03.035
Qian Yan MD, Jinlin Liu MD, PhD
{"title":"In Situ Detection of Programmed Cell Death Protein 1 and Programmed Death Ligand 1 Interactions as a Functional Predictor for Response to Immune Checkpoint Inhibition in NSCLC","authors":"Qian Yan MD,&nbsp;Jinlin Liu MD, PhD","doi":"10.1016/j.jtho.2025.03.035","DOIUrl":"10.1016/j.jtho.2025.03.035","url":null,"abstract":"","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":"20 7","pages":"Pages e86-e87"},"PeriodicalIF":21.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144548361","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Decision Trees and Random Forests: Nonlinear and Nonparametric Alternatives to Logistic Regression in Biological Data Analysis 决策树和随机森林:生物数据分析中逻辑回归的非线性和非参数替代方案
IF 21 1区 医学
Journal of Thoracic Oncology Pub Date : 2025-07-01 DOI: 10.1016/j.jtho.2025.03.003
Yoshiyasu Takefuji PhD
{"title":"Decision Trees and Random Forests: Nonlinear and Nonparametric Alternatives to Logistic Regression in Biological Data Analysis","authors":"Yoshiyasu Takefuji PhD","doi":"10.1016/j.jtho.2025.03.003","DOIUrl":"10.1016/j.jtho.2025.03.003","url":null,"abstract":"","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":"20 7","pages":"Pages e84-e85"},"PeriodicalIF":21.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144549076","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信